Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

Abstract:

CONTEXT:This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required. METHODS:A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nominal group technique. Workshop findings were recorded using extensive note taking, and summarized using thematic data analysis. The workshop was complemented by structured literature searches. RESULTS:The key finding emerging from the workshop, using an economic perspective, was that two distinct, but linked, interpretations of the concept of PM exist (personalization by 'physiology' or 'preferences'). These interpretations involve specific challenges for the design and conduct of economic evaluations. Existing evaluative (extra-welfarist) frameworks were generally considered appropriate for evaluating PM. When 'personalization' is viewed as using physiological biomarkers, challenges include representing complex care pathways; representing spillover effects; meeting data requirements such as evidence on heterogeneity; and choosing appropriate time horizons for the value of further research in uncertainty analysis. When viewed as tailoring medicine to patient preferences, further work is needed regarding revealed preferences, e.g. treatment (non)adherence; stated preferences, e.g. risk interpretation and attitude; consideration of heterogeneity in preferences; and the appropriate framework (welfarism vs. extra-welfarism) to incorporate non-health benefits. CONCLUSIONS:Ideally, economic evaluations should take account of both interpretations of PM and consider physiology and preferences. It is important for decision makers to be cognizant of the issues involved with the economic evaluation of PM to appropriately interpret the evidence and target future research funding.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Rogowski W,Payne K,Schnell-Inderst P,Manca A,Rochau U,Jahn B,Alagoz O,Leidl R,Siebert U

doi

10.1007/s40273-014-0211-5

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

49-59

issue

1

eissn

1170-7690

issn

1179-2027

journal_volume

33

pub_type

杂志文章
  • A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting.

    abstract:BACKGROUND AND AIM:Buprenorphine offers an alternative to methadone in the treatment of heroin dependence, and has the advantage of allowing alternate-day dosing. This study is the first to examine the cost effectiveness of buprenorphine as maintenance treatment for heroin dependence in a primary care setting using eco...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200523010-00007

    authors: Harris AH,Gospodarevskaya E,Ritter AJ

    更新日期:2005-01-01 00:00:00

  • A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.

    abstract:BACKGROUND:Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low d...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321001-00001

    authors: Wilson K,Marriott J,Fuller S,Lacey L,Gillen D

    更新日期:2003-01-01 00:00:00

  • Evaluation of the pharmacoeconomic literature.

    abstract::Pharmacoeconomics identifies, measures, and compares the costs and consequences of pharmaceutical products and services. The cost effectiveness of a pharmacotherapy in a particular indication depends on the molecular configuration of the drug, its safety and efficacy, and local market factors such as the acquisition ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199406040-00002

    authors: Milne RJ

    更新日期:1994-10-01 00:00:00

  • Integer/linear mathematical programming models: a tool for allocating healthcare resources.

    abstract::In today's environment, the demand for efficient healthcare resource allocation is increasing. As new technologies become available, allocation decisions become more complex and tools to assist decision makers in determining efficient allocations of healthcare resources are encouraged. Mathematical programs have multi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321120-00001

    authors: Earnshaw SR,Dennett SL

    更新日期:2003-01-01 00:00:00

  • Economic benefits of amlodipine treatment in patients with coronary artery disease.

    abstract:OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200220080-00005

    authors: Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

    更新日期:2002-01-01 00:00:00

  • Quality of life in patients with epilepsy and impact of treatments.

    abstract::Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200220150-00002

    authors: Berto P

    更新日期:2002-01-01 00:00:00

  • Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

    abstract:BACKGROUND:The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. OBJECTIVE:The aim...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0048-3

    authors: Simpson KN,Pei PP,Möller J,Baran RW,Dietz B,Woodward W,Migliaccio-Walle K,Caro JJ

    更新日期:2013-05-01 00:00:00

  • Healthcare resource and lost labour costs of migraine headache in the US.

    abstract::Migraine headache is responsible for significantly more healthcare resource and lost labour costs than previously reported. Costs associated with migraine were assessed via a survey conducted in 940 patients, 70% of whom responded. All met the International Headache Society's diagnostic criteria for migraine and had ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199202010-00008

    authors: Osterhaus JT,Gutterman DL,Plachetka JR

    更新日期:1992-07-01 00:00:00

  • Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

    abstract::The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single technology appraisal (STA...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11589310-000000000-00000

    authors: Scotland G,Waugh N,Royle P,McNamee P,Henderson R,Hollick R

    更新日期:2011-11-01 00:00:00

  • The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial.

    abstract:BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-015-0324-5

    authors: Meads DM,Marshall A,Hulme CT,Dunn JA,Ford HE

    更新日期:2016-01-01 00:00:00

  • Introduction to the pharmacoeconomics of herbal medicines.

    abstract::This article explores the need to perform pharmacoeconomic evaluations of herbal medicines and assesses the extent to which this approach has been applied so far to these products. There seems to be no compelling need for pharmacoeconomic analyses of herbal over-the-counter medicines, but such analyses are certainly w...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200018010-00001

    authors: De Smet PA,Bonsel G,Van der Kuy A,Hekster YA,Pronk MH,Brorens MJ,Lockefeer JH,Nuijten MJ

    更新日期:2000-07-01 00:00:00

  • Barrett's oesophagus: a review of costs of the illness.

    abstract::Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200119100-00003

    authors: Arguedas MR,Eloubeidi MA

    更新日期:2001-01-01 00:00:00

  • Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

    abstract:BACKGROUND:In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that have therapeutic added value in com...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11539850-000000000-00000

    authors: Hoomans T,Severens JL,van der Roer N,Delwel GO

    更新日期:2012-03-01 00:00:00

  • Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

    abstract:BACKGROUND:Bipolar disorder has a significant impact upon a patient's quality of life, imposing a considerable economic burden on the individual, family members and society as a whole. Several medications are indicated for the acute treatment of mania and depression associated with bipolar disorder as well as for maint...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11594930-000000000-00000

    authors: Ekman M,Lindgren P,Miltenburger C,Meier G,Locklear JC,Chatterton ML

    更新日期:2012-06-01 00:00:00

  • The role of models within economic analysis: focus on type 2 diabetes mellitus.

    abstract::Economic analysis of healthcare interventions is increasingly reliant on decision models to estimate the long-term costs and benefits of new therapies. Models permit analysts to take short-term clinical data to forecast long-term costs and benefits. Models should follow certain basic principles and can be appraised in...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200220001-00002

    authors: Coyle D,Lee KM,O'Brien BJ

    更新日期:2002-01-01 00:00:00

  • Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.

    abstract::Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199813020-00007

    authors: Gupta AK

    更新日期:1998-02-01 00:00:00

  • Measuring the effect of cancer on health-related quality of life.

    abstract::Measuring health-related quality of life in patients with cancer has focused primarily on the development of reliable and valid instruments (questionnaires), and on the effect of chemotherapy in phase III clinical trials. From this research several important lessons have emerged, such as: (i) the need to measure multi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199507040-00005

    authors: Osoba D

    更新日期:1995-04-01 00:00:00

  • Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

    abstract:INTRODUCTION:Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/ glycosylated haemoglobin A1c (HbA1c) after the failure of metformin mon...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200624001-00003

    authors: Beale S,Bagust A,Shearer AT,Martin A,Hulme L

    更新日期:2006-01-01 00:00:00

  • Towards a research agenda for pharmaceutical issues.

    abstract::Currently, the most important issue in US pharmaceutical policy is probably cost containment. Research into pharmaceutical issues should therefore concentrate on this area. Analysis of changing trends in pharmaceutical expenditures, particularly during the early 1990s, would be a useful starting point. Research into t...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199600102-00019

    authors: Meyer PR

    更新日期:1996-01-01 00:00:00

  • The economics of a pharmacy-based central intravenous additive service for paediatric patients.

    abstract::This study was designed to compare the costs of a pharmacy-based Central Intravenous Additive Service (CIVAS) with those of traditional ward-based preparation of intravenous doses for a paediatric population. Labour costs were derived from timings of preparation of individual doses in both the pharmacy and ward by an ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199610040-00007

    authors: Armour DJ,Cairns CJ,Costello I,Riley SJ,Davies EG

    更新日期:1996-10-01 00:00:00

  • The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

    abstract:OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-019-00838-w

    authors: Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

    更新日期:2019-12-01 00:00:00

  • Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

    abstract::Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199712060-00008

    authors: Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

    更新日期:1997-12-01 00:00:00

  • A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values.

    abstract::Economic analysts are increasingly likely to rely on systematic reviews and meta-analyses of health state utility values to inform the parameter inputs of decision-analytic modelling-based economic evaluations. Beyond the context of economic evaluation, evidence from systematic reviews and meta-analyses of health stat...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-018-0670-1

    authors: Petrou S,Kwon J,Madan J

    更新日期:2018-09-01 00:00:00

  • A model to compute the medical cost of patients in intensive care.

    abstract:OBJECTIVE:Our objective was to identify, among the information routinely collected on patients in intensive care units (ICUs), data that determine the total cost for a given patient. DESIGN:We developed a model that could help physicians in medical ICUs to estimate the cost of care for their patients when no cost data...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199915060-00005

    authors: Chaix C,Durand-Zaleski I,Alberti C,Brun-Buisson C

    更新日期:1999-06-01 00:00:00

  • 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.

    abstract::To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11312720-000000000-00000

    authors: Neumann PJ,Fang CH,Cohen JT

    更新日期:2009-01-01 00:00:00

  • Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst Scaling.

    abstract:BACKGROUND:The measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited. OBJECTIVE:The objective of this study was to evaluate the feasibili...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00884-9

    authors: Dalziel K,Catchpool M,García-Lorenzo B,Gorostiza I,Norman R,Rivero-Arias O

    更新日期:2020-05-01 00:00:00

  • Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

    abstract::Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,meta分析

    doi:10.2165/00019053-199405060-00005

    authors: Cramer MP,Saks SR

    更新日期:1994-06-01 00:00:00

  • Replicating Health Economic Models: Firm Foundations or a House of Cards?

    abstract::Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0553-x

    authors: Bermejo I,Tappenden P,Youn JH

    更新日期:2017-11-01 00:00:00

  • Incorporation of uncertainty in health economic modelling studies.

    abstract::In a recent leading article in PharmacoEconomics, Nuijten described some methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are found to suffer from seriou...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523060-00001

    authors: O'Hagan A,McCabe C,Akehurst R,Brennan A,Briggs A,Claxton K,Fenwick E,Fryback D,Sculpher M,Spiegelhalter D,Willan A

    更新日期:2005-01-01 00:00:00

  • The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.

    abstract:BACKGROUND:Dengue disease poses a great economic burden in Malaysia. METHODS:This study evaluated the cost effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives using a dynamic transmission mathematical model. The model incorporated sensitivity analyses, Malaysia-speci...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-017-0487-3

    authors: Shafie AA,Yeo HY,Coudeville L,Steinberg L,Gill BS,Jahis R,Amar-Singh Hss

    更新日期:2017-05-01 00:00:00